Skip to main content
Clinical Trials/NCT04562142
NCT04562142
Unknown
N/A

Validation of the CAD-det System, a Novel Non-Invasive Acoustic Diagnostic for the Diagnosis of Coronary Artery Disease (The CAD-det Validation Study)

AusculSciences Canada Inc.2 sites in 1 country395 target enrollmentMarch 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
AusculSciences Canada Inc.
Enrollment
395
Locations
2
Primary Endpoint
CAD-det to validate:
Last Updated
5 years ago

Overview

Brief Summary

The purpose of the study is to collect acoustic, ECG, and clinical data from consenting participants, so that AusculSciences can perform analysis on the sounds produced by the heart and determine the accuracy of the CAD-det System for detecting CAD.

Detailed Description

This is a prospective multi-center clinical trial. Using the CAD-det, acoustic and electrical cardiac data will be collected from participants with intermediate pretest probability of CAD who are referred to invasive coronary angiography (ICA). The CAD-det recording will be administered prior to the scheduled ICA procedure. The data collected by CAD-det will be processed using AusculSciences' Data Analysis Application (DAA) to produce a patient's indication for CAD.

Registry
clinicaltrials.gov
Start Date
March 2021
End Date
May 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
AusculSciences Canada Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • \>/= 19 years old
  • Suspected obstructive CAD
  • Referred to ICA

Exclusion Criteria

  • Documented CAD or coronary revascularization
  • Age \< 19 years old
  • Acute coronary syndromes
  • Congenital heart disease or heart transplantation
  • Dextrocardia
  • Uncontrolled irregular heart rhythm (atrial arrhythmia (fibrillation, flutter) or frequent PACs or PVCs (\>10/minute))
  • Resting heart rate \> 110 bpm
  • Known hemodynamically-significant valvular heart disease, audible diastolic murmurs, or hypertrophic or non-ischemic cardiomyopathy
  • Chest wall deformity or wounds in adhesive application areas
  • Unwillingness or inability to provide informed consent or to comply with the study protocol

Outcomes

Primary Outcomes

CAD-det to validate:

Time Frame: up to 1 Year

CAD-det to detect obstructive CAD as defined as QCA diameter stenosis greater than or equal to 50%.

Secondary Outcomes

  • CAD-det to detect:(up to 1 year)

Study Sites (2)

Loading locations...

Similar Trials